Latest Breaking News On - Gastroesophageal junction - Page 1 : comparemela.com

U S FDA ACKNOWLEDGES ASTELLAS RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

United statesUnited kingdomMoitreyee chatterjee kishoreNaoki okamuraRare diseases information centerTranslational sciencesAmerican cancer societyJapan ministry of healthNational institutes of health centerPrnewswire astellas pharma incNational cancer instituteAmerican society of clinical oncologyEnd results programDrug administrationOncology developmentAstellas pharma inc

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoJason lettmannAllison dillonAcademic gi cancer consortiumDevelopment rd expensesCompany nasdaqOncology holdings incUpcoming clinical milestones for evorpacept development pipelineAmerican society of cancer oncologyNeck cancer centerUniversity of colorado cancer centerUniversity of texas md anderson cancer centerExchange commissionDevelopment pillarsUniversity of california

Keytruda Combo Boosts Survival in Gastric Cancer Subtype

For certain patients with HER2-positive gastric cancers, a Keytruda treatment combination has shown promising survival outcomes.

Merck research laboratoriesNational cancer instituteSurvival outcomesGastroesophageal junctionMarjorie greenMerck researchGastric cancerGastroesophageal junction cancer

FDA Grants Fast Track Designation to PT886 for the Treatment of Pancreatic Cancer

PT886 (Phanes Therapeutics) received fast track designation 2 years after receiving orphan drug designation by the FDA.

United statesMing wangPhanes therapeutics incPhanes therapeuticsPatients withAdvanced gastricGastroesophageal junctionFast trackTherapeutics announces first patient dosedAnnounces clinical trial collaborationSupply agreement

BeiGene, Ltd : BeiGene s Biologics License Application for TEVIMBRA (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

BeiGene, Ltd : BeiGene s Biologics License Application for TEVIMBRA (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLiza heapesMark lanasaKyle blankenshipBeigene ltdEnd results programDrug administrationAmerican cancer societyNational cancer instituteEuropean commissionEuropean society for medical oncologyExchange commissionInternational agency for research on cancerDrug user fee actBiologics license application